Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone

Daniela Manno et al. Emerg Infect Dis. 2022 Mar.

Abstract

We explored the association of Ebola virus antibody seropositivity and concentration with potential risk factors for infection. Among 1,282 adults and children from a community affected by the 2014-2016 Ebola outbreak in Sierra Leone, 8% were seropositive for virus antibodies but never experienced disease symptoms. Antibody concentration increased with age.

Keywords: Africa; Ebola virus; IgG; Sierra Leone; antibodies; risk factors; seroprevalence; viruses; zoonoses.

PubMed Disclaimer

Figures

Figure
Figure
Flow chart of participants screened for the Ebola virus vaccine trial and subsequent seropositivity study of community members affected by the 2014–2016 Ebola outbreak, Sierra Leone.
See this image and copyright information in PMC

References

    1. Bower H, Glynn JR. A systematic review and meta-analysis of seroprevalence surveys of ebolavirus infection. Sci Data. 2017;4:160133. 10.1038/sdata.2016.133 - DOI - PMC - PubMed
    1. Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, et al.; EBL3001 study group. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. Lancet Infect Dis. 2022;22:97–109. 10.1016/S1473-3099(21)00125-0 - DOI - PMC - PubMed
    1. Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, et al.; EBL3001 study group. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2022;22:110–22. 10.1016/S1473-3099(21)00128-6 - DOI - PMC - PubMed
    1. Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, et al. Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. J Virol Methods. 2018;255:84–90. 10.1016/j.jviromet.2018.02.018 - DOI - PMC - PubMed
    1. Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, et al.; PREVAIL I Study Group. PREVAIL I Study Group. Phase 2 placebo-controlled trial of two vaccines to prevent ebola in Liberia. N Engl J Med. 2017;377:1438–47. 10.1056/NEJMoa1614067 - DOI - PMC - PubMed

Publication types